News and Announcements
Appointment of Taiwan Distributor
- Published December 15, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
• Appointment of J&H Technology Co Ltd as Optiscan’s exclusive pre-clinical distributor for Taiwan
• J&H Technology is a distributor of leading United States and European pre-clinical equipment
Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) announces that it has appointed J&H Technology as its exclusive distributor in Taiwan for the FIVE2(ViewnVivo) in the pre-clinical research market. This appointment follows the appointment of two (2) China distributors in Shanghai and Guangzhou in 2019 and a new distributor in North America in 2020. Taiwan represents an attractive market for the FIVE2 (ViewnVivo), being consistently ranked as the top knowledge economy in Asia, with its biomedical sector identified as one of the five pillar industries for its national development.
J&H Technology was founded in 2000 and has approximately 25 staff. It is a distributor for leading United States and European pre-clinical suppliers including ThermoFisher Scientific, PerkinElmer and Miltenyi Biotec.
Optiscan’s Executive Chairman Darren Lurie, said:
“The appointment of J&H Technology continues the expansion of our international distribution arrangements for the FIVE2 (ViewnVivo) in the pre-clinical research market. We are very pleased to have such a well-credentialled partner in an attractive market.”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
